[Market Focus] Celltrion Surges Over 10% on Expectations of Record-Breaking Q4 Results

Celltrion shares surged more than 10% in early trading on January 2. The buying momentum appears to be driven by expectations that the company will post record-breaking results in the fourth quarter of 2025.

As of 10:36 a.m. on this day, Celltrion shares were trading at 199,800 won on the Korea Exchange, up 10.39% from the previous session. The stock opened at 188,800 won and at one point during the session climbed as high as 200,000 won.

On December 31, a market holiday, Celltrion announced its forecast that consolidated sales for the fourth quarter of 2025 would reach 1.2839 trillion won, with operating profit at 472.2 billion won. The company explained that sales are expected to rise 20.7% year-on-year and operating profit by 140.4%, marking the highest-ever quarterly sales and operating profit in the company’s history.

Kwon Hae-soon, a researcher at Eugene Investment & Securities, said, “A new product mix and cost controls are expected to deliver an earnings surprise that exceeds market consensus,” and raised the target price to 250,000 won.

Seo Geunhee, a researcher at Samsung Securities, also raised the target price to 230,000 won, stating, “Profitability has recovered, driven by the growth of new products, and Celltrion’s market share in the United States is expected to become even more solid.”

On this day, news that Eli Lilly had completed the relocation of its biopharmaceutical manufacturing facility in Branchburg, New Jersey, also had a positive impact on Celltrion’s share price.